Comparative Pharmacology
Head-to-head clinical analysis: INCRUSE ELLIPTA versus SPIRIVA RESPIMAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCRUSE ELLIPTA versus SPIRIVA RESPIMAT.
INCRUSE ELLIPTA vs SPIRIVA RESPIMAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Umeclidinium is a long-acting muscarinic antagonist (LAMA). It competitively inhibits M3 muscarinic receptors in the airways, reducing acetylcholine-induced bronchoconstriction and mucus secretion.
Long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine at M3 receptors in bronchial smooth muscle, leading to bronchodilation.
Inhalation: 1 inhalation (62.5 mcg umeclidinium) once daily.
2 actuations (2.5 mcg tiotropium/actuation) once daily by oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 11 hours (range 10–13 hours) after inhalation, supporting once-daily dosing.
Terminal elimination half-life of 27 hours after inhalation (range 13-50 hours), supporting once-daily dosing due to prolonged receptor binding.
Umeclidinium is eliminated primarily by hepatic metabolism and biliary excretion; after oral administration, approximately 58% of the dose is excreted in feces (mostly as parent drug) and about 22% in urine. Renal excretion of unchanged drug is minimal (<1%).
Renal excretion (60-70% unchanged) and biliary/fecal excretion (30-40%) after IV administration; after inhalation, most of the swallowed dose is eliminated fecally.
Category C
Category C
Anticholinergic Bronchodilator
Anticholinergic Bronchodilator